Payment overview · 2025
General Payments
$2,422.68
118 reported records · 15 companies
Healthcare provider profile · identity verified
Harvey Hashimoto, MD
Allopathic & Osteopathic Physicians|Family Medicine · LODI, CA · NPI 1578506952
Verified facts
What the public records show
CMS Open Payments records show Harvey Hashimoto, MD received $2,422.68 in general payments during 2025 across 118 reported records.
MIMEDX Group, Inc. accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $1,004.16 | 41.5% | 69 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $535.61 | 22.1% | 15 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $214.57 | 8.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $134.90 | 5.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.19 | 4.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $96.34 | 4.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.30 | 3.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.28 | 2.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.47 | 2.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.08 | 1.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.82 | 1.2% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.26 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.15 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.36 | 0.8% | 1 | 2025 |
| Molnlycke Health Care US, LLC | Unresolved — no canonical attribution shown | $17.19 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,422.68 | 118 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $248.88 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $184.60 | 9 | 2025 |
Source payment records
|
|||||
| URGOCLEAN AG Normalized: urgoclean ag |
Device | Urgo Medical North America, LLC | $155.31 | 1 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $145.01 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $134.90 | 4 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $102.13 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $96.34 | 4 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $88.22 | 4 | 2025 |
Source payment records
|
|||||
| REGRANEX Normalized: regranex |
Drug | Smith+Nephew, Inc. | $86.68 | 6 | 2025 |
Source payment records
|
|||||
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $85.73 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS GO v2 HOME Normalized: renasys go v2 home |
Device | Smith+Nephew, Inc. | $85.73 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.14 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $56.28 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $56.28 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.08 | 2 | 2025 |
Source payment records
|
|||||
| URGOK2 Normalized: urgok2 |
Device | Urgo Medical North America, LLC | $30.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.82 | 2 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| Iodosorb Ointment 40g USA Normalized: iodosorb ointment 40g usa |
Device | Smith+Nephew, Inc. | $25.25 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Exufiber Normalized: exufiber |
Device | Molnlycke Health Care US, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Mepilex Border Flex Normalized: mepilex border flex |
Device | Molnlycke Health Care US, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Mepitel One Normalized: mepitel one |
Device | Molnlycke Health Care US, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Mextra Superabsorbant Normalized: mextra superabsorbant |
Device | Molnlycke Health Care US, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 249 | 35 |
| Lisinopril | Lisinopril | 78 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 78 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 71 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | 17 |
| Lorazepam | Lorazepam | 59 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 41 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 41 |
| Furosemide | Furosemide | 50 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 13 |
| Amlodipine Besylate | Amlodipine Besylate | 42 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Jardiance | Empagliflozin | 38 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Omeprazole | Omeprazole | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 33 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 19 |
| Fentanyl | Fentanyl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Gabapentin | Gabapentin | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Losartan Potassium | Losartan Potassium | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Linezolid | Linezolid | 22 | 17 |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,422.68 · 118 records | MIMEDX Group, Inc. | AREXVY, COLLAGENASE SANTYL, Cologuard Collection Kit, DALVANCE, Exufiber, FREESTYLE LIBRE 3, Flexitouch Plus, GEMTESA, GRAFIX, GRAFIX PL, Iodosorb Ointment 40g USA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, Mepilex Border Flex, Mepitel One, Mextra Superabsorbant, Nimbl, OASIS, Ozempic, REGRANEX, RENASYS GO v2 HOME, RENASYS TOUCH, SHINGRIX, URGOCLEAN AG, URGOK2, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VRAYLAR, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error